Hostname: page-component-7b7567c8c-wxvwp Total loading time: 0 Render date: 2026-11-15T07:36:29.816Z Has data issue: false hasContentIssue false
  • English
  • Français

[3H]Pirenzepine binding in the pathology of schizophrenia: studies in Brodmann's area 6

Published online by Cambridge University Press:  24 June 2014

A Soulby,
B Dean and
E Scarr
A Soulby
Affiliation:
Mental Health Research Institute, Melbourne, Australia
B Dean
Affiliation:
Mental Health Research Institute, Melbourne, Australia
E Scarr
Affiliation:
Mental Health Research Institute, Melbourne, Australia
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

Information

Type
Abstracts from ‘Brainwaves’— The Australasian Society for Psychiatric Research Annual Meeting 2006, 6–8 December, Sydney, Australia
Information
Acta Neuropsychiatrica , Volume 18 , Issue 6 , December 2006, pp. 308
Copyright
Copyright © 2006 Blackwell Munksgaard

Background:

Changes in muscarinic receptors are widespread in the brains of subjects with schizophrenia, implicating them in the pathology of the disorder (Hyde & Crook Chem Neuroanat 2001, 22 53–63). A previous study showed decreased levels of mRNA for the muscarinic M1 receptor in Brodmann's area (BA) 6 from subjects with schizophrenia (Mancama et al. Am J Med Genet B Neuropsychiatr Genet 2003, 119 2–6). The purpose of our study was to further investigate this finding.

Methods:

Using in situ radioligand binding and autoradiography, the density of [3H]pirenzepine binding was determined in BA 6 obtained postmortem from 20 subjects with schizophrenia and 20 subjects with no psychiatric history (controls).

Results:

[3H]Pirenzepine binding was differentially distributed in the cortical gray matter (inner layer = gray1; outer layer = gray2). [3H]Pirenzepine binding was significantly lower in tissue from subjects with schizophrenia than in that from control subjects in both gray1 (mean ± SEM, 74.56 ± 10.67 vs. 118.80 ± 5.47 fmol//mgETE, P < 0.01) and gray2 layers (102.90 ± 14.09 vs. 152.90 ± 8.04, P < 0.01). Furthermore, [3H]pirenzepine binding was significantly different between layers in control subject tissue (gray1, 118.80 ± 5.47; gray2, 152.90 ± 8.04; P < 0.05), but not in that from subjects with schizophrenia (gray1, 74.56 ± 10.67; gray2 102.90 ± 14.09; P > 0.05).

Conclusion:

These results support previous findings that levels of M1 and/or M4 muscarinic receptors are significantly altered in cortical regions from subjects with schizophrenia, extending the regions affected to include BA6.